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Background: Less than 67% of patients with intermediate risk for common bile duct (CBD) stones require
therapeutic intervention. It is important to have an accurate, safe, and reliable method for the definitive diagnosis
of CBD stones before initiating therapeutic endoscopic retrograde cholangiopancreatography (ERCP). Few
publications detail the diagnostic efficacy of linear echoendoscopy (EUS) for CBD stones.
Methods: 30 patients with biliary colic, pancreatitis, unexplained derangement of liver function tests, and/or dilated
CBD without an identifiable cause were enrolled in the study. When a CBD stone was disclosed by linear EUS, ERCP
with stone extraction was performed. Patients who failed ERCP were referred for surgical intervention. If no stone
was found by EUS, ERCP would not be performed and patients were followed-up for possible biliary symptoms for
up to three months.
Results: The major reason for enrollment was acute pancreatitis. The mean predicted risk for CBD stones was 47%
(28–61). Of the 12 patients who were positive for CBD stones by EUS, nine had successful ERCP, one failed ERCP
(later treated successfully by surgical intervention) and two were false-positive cases. No procedure-related adverse
events were noted. For those 18 patients without evidence of CBD stones by EUS, no false-negative case was noted
during the three-month follow-up period. Linear EUS had sensitivity, specificity, positive and negative predicted
values for the detection of CBD stones of 1, 0.9, 0.8 and 1, respectively.
Conclusion: Linear EUS is safe and efficacious for the diagnosis of occult CBD stones in patients with intermediate
risk for the disease.
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Common bile duct (CBD) stone is a common clinical
problem that can cause serious complications, such as
acute cholangitis and pancreatitis [1]. Between 3 to 33%
of patients with symptomatic gallstones have associated
CBD stones [2].
Neither clinical/biochemical data, transabdominal ul-
trasound, and computed tomography (CT) can accur-
ately predict the presence of CBD stones. The sensitivity
and specificity of CT in diagnosing CBD stones are 77%* Correspondence: khlai@vghks.gov.tw; wbrugge@partners.org
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reproduction in any medium, provided the orand 72%. The diagnostic rate of CT is significantly lower
in patients with stone size < 5 mm than in patients with
stone size ≧ of 5 mm (57% vs. 81%) [3].
Endoscopic retrograde cholangiopancreatography (ERCP)
remains the gold standard for both diagnosis and treat-
ment of CBD stones; however, the procedure is associated
with an overall complication rate of 5–10% and mortality
rate of 0.02–0.5% [4-7]. It has been shown that the rate
of post-ERCP pancreatitis may be as high as 15%, which
includes 1% of patients graded as severe in degree [8].
This is true in high risk patients such as suspected
sphincter of Oddi dysfunction, but not bile duct stones.
Less than 67% of patients with an intermediate risk for
CBD stones (occult CBD stones) require therapeutic
intervention [2,9,10]. Thus, over 30% of patients withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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curate, safe, and efficacious method is needed to diagnose
CBD stones in a definitive manner.
Magnetic resonance cholangiopancreatography (MRCP)
has emerged as a non-invasive method to evaluate the bil-
iary system [11]. It is beneficial in that it requires no sed-
ation, involves no radiation exposure, and is free of
complication. However, the equipment is rather expensive
and not commonly available in every hospital. Moreover,
the diagnostic rate is dramatically decreased for smaller
CBD stones (≦5 mm, sensitivity: 67%) [12]. Radial
echoendoscopy (EUS), on the other hand, is a minimally
invasive procedure that has a low procedural risk similar
to ordinary gastroscopy. It is an excellent method for
examining the CBD and has been proven to have diagnos-
tic accuracy comparable to ERCP. In addition, the CBD
stone detection rates do not vary with stone size using ra-
dial EUS [13]. The images of biliary-pancreatic system and
the related pathology derived from radial EUS are similar
to CT scans and are convenient for guiding therapy.
Linear echoendoscopy is a newer form of EUS. As
such, there is scant published information concerning its
diagnostic efficacy for CBD stones. The aim of this study
was to investigate the safety and diagnostic accuracy of
linear EUS in detecting occult CBD stones.
Methods
This is a prospective observational study. 30 patients (ar-
bitrarily chosen) were recruited to determine the sensi-
tivity, specificity, positive and negative predicted values
of linear EUS for the diagnosis of occult bile duct stone,
as well as, possible related adverse events.
Patients
This prospective study was approved by the Institutional
Review Board of Kaohsiung Veterans General Hospital,
and written informed consent was obtained from all the
participating patients beforehand.
Between February 2009 and December 2011, 30 pa-
tients with intermediate risk (<67%) for CBD stones [2]
were enrolled in our study. Inclusion criteria involved a
manifestation of the following set of symptoms/signs at
presentation or within six months prior to admission
[14] biliary colic, unexplained derangement of liver func-
tion tests (such as total bilirubin, alkaline-phosphatase,
GOT (glutamic oxaloacetic transaminase)/GPT (glutamic
pyruvic transaminase), and γ-GT (Gamma-glutamyl trans-
ferase)), enlarged CBD ≧ 8 mm with an intact gallbladder
(GB) (≧ 10 mm in patients who had received cholecystec-
tomy) under conventional ultrasound (US) without an
identifiable cause, or any combination of the above symp-
toms/signs such as biliary pancreatitis.
Exclusion criteria included patients with acute cholan-
gitis, history of gastrectomy, sphincterotomy, or sphinc-teroplasty, possible drug- or alcohol-related liver func-
tion impairment, history of CBD stones that had already
been found by means of conventional ultrasound/CT
scan, tumor of the bile duct that had already been iden-
tified, impaired consciousness, and severe cardiovascular
or psychiatric diseases.
Diagnostic and therapeutic procedures
Local anesthesia of the pharynx was performed using
10% xylocaine, and an intramuscular injection of 40 mg
hyoscine-N-butylbromide and 25–50 mg meperidine were
administered as premedication. EUS was performed using
a linear-array echoendoscope (GF-C2000, Olympus Op-
tical, Tokyo, Japan) at 7.5 MHz frequency and ERCP was
performed with a side-view endoscope (JF-240; Olympus
Optical Corporation, Tokyo, Japan) by the same experi-
enced operator (Chan HH). A CBD stone was diagnosed
by EUS if a persistent hyperechoic lesion was noted, with
or without an acoustic shadow. Once the stone was
disclosed by EUS imagery, ERCP with stone extraction
was subsequently performed in the same section. This pro-
cedure was in compliance with the recently published
guidelines by the American Society for Gastrointestinal
Endoscopy emphasizing that CBD stones should be re-
moved if detected unless significant mitigating clinical cir-
cumstances are present [15].
After selective cannulation of the CBD using a cath-
eter, cholangiography was performed to confirm the
diagnosis of a CBD stone. A 0.035-inch guide-wire
(Boston Scientific, Corp, MA, USA) was then inserted
into the bile duct through the catheter. A dilating
balloon (CRE balloon, 5.5 cm in length, 0.8-1.2 cm in
diameter; Boston Scientific, Corp, Ireland) was passed
via the pre-positioned guide-wire into the bile duct.
Using fluoroscopic and endoscopic guidance, the balloon
was inflated with sterile saline solution up to the optimal
size and duration (usually 3–5 min) according to the
stone size and each patient’s tolerance. In order to
minimize the risk of perforation, the size of the balloon
must not exceed the size of the CBD. After removal of
the balloon and guide-wire, the stones were removed
using a Dormia basket or balloon-tipped catheter. Each
patient was observed in the hospital for at least 24 hours
after endoscopic treatment. Procedure-related adverse
events were recorded according to the definitions and
grading systems of the recent workshop held by the
American Society of Gastrointestinal Endoscopy [16].
Clinical evaluation of each patient’s symptoms and serum
amylase was performed the following day.
The patients with positive CBD stones found by EUS
who subsequently failed ERCP procedures were referred
for surgical intervention. If no stone was found by
EUS, ERCP would not be performed and patients were
followed-up in the outpatient clinic or via telephone for
Figure 1 The flow-chart outlines how patients with CBD stones found by linear EUS are sent for treatment (ERCP/surgery), while
patients with negative findings are followed up for up to three months.
Table 1 Patient characteristics
Sex(M/F) 20/10
Age (mean ± SD) 60.17 ± 15.08 y/o
Intact GB (GB stone) 26 (15)
Juxtapapillary diverticulum(+/−) 7/23
Reasons for inclusion Number of patients
Acute pancreatitis 15
Abdominal pain 1
Abdominal liver function 1
Dilated bile duct 2
Abdominal pain + Abnormal
liver function
5
Abdominal pain + dilated bile duct 2
Abdominal pain + Abnormal liver
function + dilated bile duct
4
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three months. In the case of recurrence of biliary symp-
toms that necessitated further treatment during the
follow-up period, patients were admitted for ERCP on
an in-patient basis or referred for surgical treatment.
Figure 1 shows a flow-chart summarizing our study
plan.
Patients with stones correctly identified by EUS who
were subsequently proved by ERCP or surgery were con-
sidered true positive. Patients who had no stones, but
were incorrectly diagnosed by EUS and subsequently
disclosed by ERCP (with bile analysis) or surgery were
considered false positive. Patients who had no stones,
but were correctly diagnosed by EUS and found to have
no biliary symptoms during the follow-up period, were
considered true negative. Patients who had stones in
their bile ducts, but were missed by EUS and finally
found to be symptomatic during the period of follow-up,
were considered false negative.
Results
Between February 20, 2009 and December 31, 2010, 30
patients were enrolled in the study. Characteristics of
patients and reasons for their enrollment are shown in
Table 1. Two-thirds of the patients were male (mean
age: 60.17 ± 15.08 years). Most patients (26 out of 30)
had an intact gallbladder, and among them, 15 patients
had GB stones. Moreover, seven patients possessed a
juxtapapillary diverticulum.
The major reason for enrollment was acute pancrea-
titis (15 patients). In addition to pancreatitis, these 15
patients presented with at least one or more of the fol-
lowing signs of CBD stones, which include: jaundice
(eight patients), dilated CBD (five patients), GB stones
(nine patients) and elevated Alkaline-phosphatase and
Gamma-glutamyltransferase (10 patients). No directevidence of CBD stones was found by means of trans-
abdominal ultrasound (30 patients) and CT scan (24 pa-
tients, others did not receive CT scan exam). The mean
predicted risk for CBD stone was 47% (28–61) [9].
Of the 12 patients who were positive for CBD stones
by EUS (Figure 2), eight were treated successfully using
ERCP in the same section. One patient, who had failed
in the same section of EUS, was treated successfully by
ERCP 32 days later following the refusal of surgery by
patient. Another one failed ERCP and was later treated
successfully by surgical extraction. There were two false-
positive cases. In one, no gross stone was extracted dur-
ing ERCP procedure, and no stone crystal was found in
the aspirated bile under the microscopic exam. Thera-
peutic ERCP failed for the other case and the absence of
a stone was proved by surgery. All detected stones were
≦ 5mm in size except one (which measured 0.85 mm in
diameter). All patients tolerated both endoscopic
Figure 2 (A) A tiny CBD stone is revealed using linear EUS. (B) However, no definite filling defect is seen in the ERCP picture. (C) and (D) A
tiny yellowish CBD stone is extracted after balloon dilation is applied.
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events were noted. For those 18 patients who had no
evidence of stones by EUS, no false-negative case was
noted during the three- month follow-up period
(Figure 3).
In the current study, sensitivity, specificity, positive
and negative predicted values of linear EUS for the de-
tection of occult CBD stones were 1, 0.9, 0.8 and 1,
respectively.Figure 3 12 patients were positive for CBD stones found by linear EU
no false negative noted during the 3 months of follow-up.Discussion
Systematic review has shown that there was no signifi-
cant difference between EUS and MRCP for the detec-
tion of choledocholithiasis [11]. The choice of the
equipment depends on availability, physician’s experi-
ence, and cost considerations.
MRCP is, theoretically, more objective in the diagnosis
of biliary diseases than EUS or ERCP. However, patients
with claustrophobic tendencies may obviate its use. InS. 10 were true positive. 18 patients were negative for CBD stones and
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which is more costly to operate. It is available only in
medical centres where a group of experienced radiolo-
gists team up to interpret the MRCP images. MRCP is
especially useful for potentially occult CBD stones that
fail to be discovered by conventional ultrasound or CT
scans, as in our cases. However, the different properties
of MRCP compared to EUS/ERCP require a different
type of patient preparation, rendering it inconvenient to
perform subsequent therapeutic ERCP immediately after
MRCP, in the event that CBD stones are identified. On
the other hand, linear EUS, compared to MRCP, is more
portable and less costly to operate. In addition, although
the learning curve for linear EUS is steep, it is econom-
ically feasible to train a small group of endoscopy fellows
within the same hospital to perform the procedure.
Quality images can be obtained from linear EUS and
they can be further improved by adjusting either the
contrast or brightness in real time, as well as by manipu-
lating the relative distance, location and direction of the
tip of the endoscope to the target lesion. It is also easy
to interpret linear EUS images due to the proximity of
the EUS probe to the CBD, which excludes intestinal gas
interference. Although, linear EUS is more invasive than
MRCP, the procedure-associated risk of performing lin-
ear EUS is similar to ordinary upper gastrointestinal en-
doscopy and lower compared to ERCP.
A previous report [14] has shown that linear EUS is a
reliable method for the evaluation of patients with high
risk for CBD stones. Furthermore, it has been previously
reported [17] that a considerable portion of patients with
intermediate risk of CBD stones (as in our current study
consisting of a group of patients with no direct evidence
of CBD stone found by transabdominal ultrasound/CT
scan) have no evidence of stones by linear EUS, thus,
avoiding unnecessary invasive evaluation of the bile duct
with ERCP.
National health policy has a major impact on our
study. In Taiwan; all citizens are included in National
Health Insurance. Each citizen and their family receive
fairly effective medical care in exchange for less than 10%
of their salary. However, this poses a large financial bur-
den on the government. It is, therefore, not cost-effective
to administer conscious sedation to every patient receiv-
ing an endoscopic exam. This financial consideration has
a psychological impact on patients experiencing the ne-
cessity to change to the side-view duodenoscope when
they needed a therapeutic ERCP immediately after CBD
stones were found by EUS.
In addition, there is no “gold standard” for the detec-
tion of CBD stones in the study. Since ERCP has been
performed only in patients with positive CBD stone by
EUS and follow-up of patients has, in part, been
conducted just by telephone, the rate of false negativefindings may be underestimated. Another shortcoming
of the study is that both EUS and ERCP were performed
by the same investigator, and no blinding has been
performed.Conclusions
This study suggests that linear EUS can accurately detect
CBD stones in patients with intermediate risk for the
disease, when conventional imaging techniques have
failed. This procedure can, therefore, minimize the num-
ber of unnecessary invasive ERCP procedures for this
subset of patients. There were no procedural-related ad-
verse events caused by the use of linear EUS for the
diagnosis of CBD stones. However, one drawback to our
study involved the need to change to the side-view
duodenoscope when patients required ERCP treatment.
Hopefully, future technological advancement will pro-
vide an endoscope that enables performance of both
EUS and ERCP.
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